| Literature DB >> 31910839 |
Beata Dolka1, Michał Czopowicz2, Dorota Chrobak-Chmiel3, Aleksandra Ledwoń4, Piotr Szeleszczuk4.
Abstract
BACKGROUND: This study was aimed to investigate the intestinal microbiota in racing pigeons with regard to Enterococcus species distribution, virulence factors and antibiotic susceptibility. Three methods (API, Multiplex sodA-PCR, 16S rRNA sequencing) were compared for Enterococcus species identification. Cloacal samples from 179 apparently healthy pigeons of 13 different flocks were tested.Entities:
Keywords: Antimicrobial resistance; Enterococcus; Racing pigeons; VRE; Virulence factors
Mesh:
Substances:
Year: 2020 PMID: 31910839 PMCID: PMC6947970 DOI: 10.1186/s12917-019-2200-6
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Prevalence of particular Enterococcus species (n = 145) in racing pigeons
| Number of isolates | Prevalence (CI 95%) | |
|---|---|---|
| 50 | 34.5 (27.2, 42.5) | |
| 30 | 20.7 (14.9, 28.0) | |
| 17 | 11.7 (7.5, 18.0) | |
| 17 | 11.7 (7.5, 18.0) | |
| 13 | 9 (5.3, 14.7) | |
| 7 | 4.8 (2.4, 9.6) | |
| 5 | 3.4 (1.5, 7.8) | |
| 3 | 2.1 (0.7, 5.9) | |
| 3 | 2.1 (0.7, 5.9) |
Percent of positive reactions (%) in rapid ID 32 STREP (bioMérieux, France) for Enterococcus species (n = 145) isolated from racing pigeons
| Parameter | Chi-square test | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ADH | 22.0↓ | 93.3 | 100 | 94.1 | 92.3 | 100 | 40.0↓ | 33.3↓ | 100 | < 0.001 |
| βGLU | 92.0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.365 |
| βGAR | 78.0 | 43.3↓ | 5.9↓ | 23.5↓ | 38.5↓ | 42.9↓ | 20.0↓ | 66.7 | 66.7 | < 0.001 |
| βGUR | 6.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.590 |
| αGAL | 96.0 | 90.0 | 29.4↓ | 70.6 | 92.3 | 100 | 80.0 | 100 | 66.7 | < 0.001 |
| PAL | 46.0↑ | 3.3 | 0 | 0 | 7.7 | 0 | 0 | 66.7↑ | 0 | < 0.001 |
| RIB | 100 | 100 | 100 | 100 | 100 | 85.7 | 100 | 100 | 100 | 0.624 |
| MAN | 76.0 | 13.3↓ | 100 | 100 | 100 | 71.4 | 100 | 100 | 33.3↓ | < 0.001 |
| SOR | 88.0 | 23.3↓ | 88.2 | 29.4↓ | 0↓ | 28.6↓ | 60.0 | 66.7 | 33.3 | < 0.001 |
| LAC | 98.0 | 96.7 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.960 |
| TRE | 96.0 | 80.0 | 100 | 88.2 | 100 | 57.1↓ | 80.0 | 100 | 100 | 0.019 |
| RAF | 100.0 | 43.3 | 29.4↓ | 47.1↓ | 92.3 | 28.6↓ | 80.0 | 100 | 66.7 | < 0.001 |
| VP | 86.0 | 83.3 | 76.5 | 88.2 | 69.2 | 85.7 | 80.0 | 66.7 | 100 | 0.829 |
| APPA | 14.0 | 10.0 | 5.9 | 5.9 | 0 | 14.3 | 0 | 0 | 33.3 | 0.507 |
| βGAL | 90.0 | 93.3 | 17.7↓ | 94.1 | 100 | 100 | 100 | 66.7 | 100 | < 0.001 |
| PYRA | 10.0↓ | 93.3 | 100 | 100 | 100 | 100 | 100 | 0↓ | 100 | < 0.001 |
| βNAG | 12.0↓ | 83.3 | 88.2 | 70.6 | 100 | 57.1 | 60.0 | 100 | 33.3 | < 0.001 |
| GTA | 96.0 | 90.0 | 100 | 52.9↓ | 100 | 85.7 | 80.0 | 100 | 66.7 | < 0.001 |
| HIP | 2.0↓ | 3.3↓ | 41.2 | 41.2 | 92.3↑ | 0↓ | 0↓ | 33.3 | 0↓ | < 0.001 |
| GLYG | 2.0 | 0 | 0 | 5.9 | 0 | 0 | 0 | 0 | 0 | 0.883 |
| PUL | 20.0↑ | 0 | 0 | 0 | 0 | 0 | 20.0↑ | 0 | 0 | 0.004 |
| MAL | 100 | 96.7 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0.923 |
| MEL | 100 | 86.7 | 29.4↓ | 64.7↓ | 92.3 | 28.6↓ | 80.0 | 100 | 66.7 | < 0.001 |
| MLZ | 26.0 | 0 | 82.4↑ | 11.8 | 0 | 0 | 80.0↑ | 33.3 | 0 | < 0.001 |
| SAC | 100 | 100 | 88.2 | 100 | 100 | 100 | 100 | 100 | 100 | 0.360 |
| LARA | 76.0 | 16.7↓ | 17.7↓ | 94.1 | 100 | 85.7 | 100 | 33.3↓ | 0↓ | < 0.001 |
| DARL | 48.0↑ | 3.3 | 0 | 0 | 0 | 0 | 0 | 66.7↑ | 0 | < 0.001 |
| MβDG | 66.0↓ | 96.7 | 94.1 | 100 | 100 | 100 | 100 | 100 | 100 | < 0.001 |
| TAG | 36.0 | 10.0 | 100↑ | 47.1 | 100↑ | 57.1 | 80.0↑ | 66.7↑ | 0↓ | < 0.001 |
| βMAN | 24.0↓ | 63.3 | 94.1 | 70.6 | 100 | 85.7 | 100 | 100 | 66.7 | < 0.001 |
| CDEX | 92.0 | 83.3 | 100 | 82.4 | 92.3 | 100 | 40.0↓ | 100 | 66.7 | 0.036 |
| URE | 2.0 | 0 | 0 | 5.9 | 0 | 0 | 0 | 0 | 0 | 0.883 |
ADH (arginine dihydrolase), βGLU (β-glucosidase), βGAR (β-galactosidase), βGUR (β-glucuronidase), αGAL (α-galactosidase), PAL (alkaline phosphatase), RIB (ribose), MAN (mannitol), SOR (sorbitol), LAC (lactose), TRE (trehalose), RAF (rafinose), VP (Voges Proskauer, aceton production), APPA (alanyl-phenylalanyl-proline arylamidase), βGAL (β-galactosidase), PYRA (pyroglutamic acid arylamidase), βNAG (N-acetyl-β-glucosaminidase), GTA (glycyl-tryptophan arylamidase), HIP (hydrolysis of hipurate), GLYG (glycogen), PUL (pullulane), MAL (maltose), MEL (melibiose), MLZ (melezitose), SAC (saccharose), LARA (L-arabinose), DARL (D-arabitol), CDEX (cyclodextrin), MβDG (methyl-βD-glucopyranoside), TAG (tagatose), βMAN (β-mannosidase), URE (urease)
Comparison of Multiplex sodA-PCR and 16S rRNA sequencing in identification of Enterococcus species in racing pigeons
| 16S Sequencing | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Multiplex PCR ( | 50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | |
| 2 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30 | ||
| 1 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | ||
| 0 | 0 | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 17 | ||
| 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 13 | ||
| 1 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 7 | ||
| 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 5 | ||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 3 | ||
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | ||
| Total ( | 55 | 28 | 16 | 17 | 13 | 6 | 5 | 3 | 2 | 145 | |
Cohen’s kappa = 0.956 (CI 95%: 0.919, 0.993) – almost perfect agreement
Green indicates agreement in species identification between sequencing and PCR; yellow indicates a lack of agreement
Prevalence [n, (%)] of the virulence factors in different Enterococcus species isolated from racing pigeons
| No. of isolates | Genes encoding virulence factors | |||||||
|---|---|---|---|---|---|---|---|---|
| 50 | 18 (36%) | 21 (42%) | 0 (0%) | 12 (24%) | 14 (28%) | 2 (4%) | 9 (18%) | |
| 30 | 8 (26.7%) | 8 (26.7%) | 0 (0%) | 7 (23.3%) | 7 (23.3%) | 4 (13.3%) | 9 (30%) | |
| 17 | 8 (47.1%) | 7 (41.2%) | 0 (0%) | 4 (23.5%) | 4 (23.5%) | 2 (11.8%) | 4 (23.5%) | |
| 17 | 13 (76.5%) | 13 (76.5%) | 0 (0%) | 16 (94.1%)*↑ | 13 (76.5%)*↑ | 2 (11.8%) | 10 (58.8%) | |
| 13 | 7 (53.9%) | 6 (46.2%) | 0 (0%) | 3 (23.1%) | 3 (23.1%) | 2 (15.4%) | 3 (23.1%) | |
| 7 | 3 (42.9%) | 2 (28.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (14.3%) | |
| 5 | 2 (40%) | 3 (60%) | 0 (0%) | 1 (20%) | 1 (20%) | 1 (20%) | 2 (40%) | |
| 3 | 1 (33.3%) | 2 (66.7%) | 0 (0%) | 0 (0%) | 1 (33.3%) | 0 (0%) | 1 (33.3%) | |
| 3 | 1 (33.3%) | 1 (33.3%) | 0 (0%) | 1 (33.3%) | 1 (33.3%) | 0 (0%) | 1 (33.3%) | |
| Total | 145 | 61 (42.1%) | 63 (43.5%) | 0 (0%) | 44 (30.3%) | 44 (30.3%) | 13 (9%) | 40 (27.6%) |
* p < 0.001
Results for gelatinase production by enterococci isolated from racing pigeons
| No. of isolates | Gelatinase production | |||||
|---|---|---|---|---|---|---|
| at 1 day | at 7 day | at 10 day | at 14 day | Overall | ||
| 50 | 2 (4%) | 4 (8%) | 5 (10%) | 5 (10%) | 5 (10%) | |
| 30 | 0 (0%) | 1 (3.3%) | 1 (3.3%) | 1 (3.3%) | 1 (3.3%) | |
| 17 | 1 (5.9%) | 2 (11.8%) | 2 (11.8%) | 2 (11.8%) | 2 (11.8%) | |
| 17 | 8 (53.3%)*↑ | 12 (70.6%)*↑ | 12 (70.6%)*↑ | 12 (70.6%)*↑ | 12 (70.6%)*↑ | |
| 13 | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | 1 (7.7%) | |
| 7 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| 5 | 0 (0%) | 1 (20%) | 1 (20%) | 1 (20%) | 1 (20%) | |
| 3 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| 3 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Total | 145 | 12 (8.4%) | 21 (14.5%) | 22 (15.2%) | 22 (15.2%) | 22 (15.2%) |
* p < 0.001
Antibiotic susceptibility observed in commensal enterococci isolated from racing pigeons [n, (%)]
| Amoxicillin/ clavulanic acid | Ampicillin | Penicillin | Enrofloxacin | Doxycycline | Tetracycline | Nitrofurantoin | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | I | S | R | I | S | R | I | S | R | I | S | R | I | S | R | I | S | R | I | S | |
| 0 (0) | 0 (0) | 50 (100) | 0 (0) | 0 (0) | 50 (100) | 1 (2) | 0 (0) | 49 (98) | 44 (88) | 6 (12) | 0 (0) | 39 (78) | 0 (0) | 11 (22) | 7 (14) | 30 (60) | 13 (26) | 5 (10) | 1 (2) | 44 (88) | |
| 0 (0) | 0 (0) | 30 (100) | 0 (0) | 0 (0) | 30 (100) | 4 (13.3) | 0 (0) | 26 (86.7) | 21 (70) | 9 (30) | 0 (0) | 20 (66.7) | 0 (0) | 10 (33.3) | 10 (33.3) | 9 (30) | 11 (36.7) | 17 (56.7)*↑ | 6 (20) | 7 (23.3) | |
| 0 (0) | 0 (0) | 17 (100) | 0 (0) | 0 (0) | 17 (100) | 0 (0) | 0 (0) | 17 (100) | 13 (76.5) | 4 (23.5) | 0 (0) | 7 (41.2)*↓ | 0 (0) | 10 (58.8) | 3 (17.6) | 13 (76.5) | 1 (5.9) | 14 (82.4)*↑ | 0 (0) | 3 (17.7) | |
| 0 (0) | 0 (0) | 17 (100) | 0 (0) | 0 (0) | 17 (100) | 0 (0) | 0 (0) | 17 (100) | 15 (88.2) | 2 (11.8) | 0 (0) | 17 (100) | 0 (0) | 0 (0) | 5 (29.4) | 12 (70.6) | 0 (0) | 2 (11.8) | 2 (11.8) | 13 (76.5) | |
| 0 (0) | 1 (7.7) | 12 (92.3) | 0 (0) | 0 (0) | 13 (100) | 0 (0) | 0 (0) | 13 (100) | 9 (69.2) | 4 (30.8) | 0 (0) | 12 (92.3) | 0 (0) | 1 (7.7) | 0 (0) | 13 (100) | 0 (0) | 0 (0)*↓ | 0 (0) | 13 (100) | |
| 0 (0) | 0 (0) | 7 (100) | 0 (0) | 0 (0) | 7 (100) | 0 (0) | 0 (0) | 7 (100) | 5 (71.4) | 2 (28.6) | 0 (0) | 3 (42.9)*↓ | 0 (0) | 4 (57.1) | 0 (0) | 5 (71.4) | 2 (28.6) | 1 (14.3) | 1 (14.3) | 5 (71.4) | |
| 0 (0) | 0 (0) | 5 (100) | 0 (0) | 0 (0) | 5 (100) | 0 (0) | 0 (0) | 5 (100) | 5 (100) | 0 (0) | 0 (0) | 3 (60) | 0 (0) | 2 (40) | 0 (0) | 5 (100) | 0 (0) | 1 (20) | 0 (0) | 4 (80) | |
| 0 (0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 3 (100) | 2 (66.7) | 1 (33.3) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 2 (66.7) | 1 (33.3) | 0 (0)*↓ | 0 (0) | 3 (100) | |
| 0 (0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 3 (100) | 2 (66.7) | 1 (33.3) | 0 (0) | 2 (66.7) | 0 (0) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 3 (100)*↑ | 0 (0) | 0 (0) | |
| Total ( | 0 (0) | 1 (0.7) | 144 (99.3) | 0 (0) | 0 (0) | 145 (100) | 5 (3.4) | 0 (0) | 140 (96.6) | 116 (80) | 29 (20) | 0 (0) | 106 (73.1) | 0 (0) | 39 (26.9) | 26 (17.9) | 90 (62.1) | 29 (20) | 43 (29.7) | 10 (6.9) | 92 (63.5) |
| Chloramphenicol | Erythromycin | High level gentamicin | Vancomycin | Teicoplanin | Linezolid | ||||||||||||||||
| R | I | S | R | I | S | R | I | S | R | I | S | R | I | S | R | I | S | ||||
| 11 (22)* ↑ | 8 (16) | 31 (62) | 33 (66) | 2 (4) | 15z (30) | 1 (2) | 0 (0) | 49 (98) | 5 (10) | 6 (12) | 39 (78) | 39 (78) | 0 (0) | 11 (22) | 0 (0) | 1 (2) | 49 (98) | ||||
| 1 (3.3) | 3 (10) | 26 (86.7) | 6 (20)*↓ | 4 (13.3) | 20 (66.7) | 1 (3.3) | 0 (0) | 29 (96.7) | 11 (36.7) | 4 (13.3) | 15 (50) | 20 (66.7) | 0 (0) | 10 (33.3) | 0 (0) | 0 (0) | 30 (100) | ||||
| 0 (0) | 2 (11.8) | 15 (88.2) | 6 (35.3) | 7 (41.2) | 4 (23.5) | 2 (11.8) | 0 (0) | 15 (88.2) | 3 (17.6) | 4 (23.5) | 10 (58.8) | 7 (41.2)*↓ | 0 (0) | 10 (58.8) | 0 (0) | 3 (17.6) | 14 (82.4) | ||||
| 2 (11.8) | 8 (47.1) | 7 (41.2) | 14 (82.4)*↑ | 2 (11.8) | 1 (5.9) | 0 (0) | 0 (0) | 17 (100) | 2 (11.8) | 14 (82.4) | 1 (5.9) | 17 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 17 (100) | ||||
| 0 (0) | 0 (0) | 13 (100) | 10 (76.9) | 1 (7.7) | 2 (15.4) | 0 (0) | 0 (0) | 13 (100) | 4 (30.8) | 8 (61.5) | 1 (7.7) | 12 (92.3) | 0 (0) | 1 (7.7) | 0 (0) | 0 (0) | 13 (100) | ||||
| 0 (0) | 0 (0) | 7 (100) | 1 (14.3)*↓ | 0 (0) | 6 (85.7) | 0 (0) | 0 (0) | 7 (100) | 0 (0) | 1 (14.3) | 6 (85.7) | 3 (42.9)*↓ | 0 (0) | 4 (57.1) | 0 (0) | 0 (0) | 7 (100) | ||||
| 0 (0) | 0 (0) | 5 (100) | 0 (0)*↓ | 4 (80) | 1 (20) | 0 (0) | 0 (0) | 5 (100) | 2 (40) | 2 (40) | 1 (20) | 3 (60) | 0 (0) | 2 (40) | 0 (0) | 0 (0) | 5 (100) | ||||
| 1 (33.3)* ↑ | 0 (0) | 2 (66.7) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 (0) | 0 (0) | 3 (100) | 0 (0) | 1 (33.3) | 2 (66.7) | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 1 (33.3) | 2 (66.7) | ||||
| 0 (0) | 0 (0) | 3 (100) | 1 (33.3) | 0 (0) | 2 (66.7) | 0 (0) | 0 (0) | 3 (100) | 1 (33.3) | 0 (0) | 2 (66.7) | 2 (66.7) | 0 (0) | 1 (33.3) | 0 (0) | 0 (0) | 3 (100) | ||||
| Total ( | 15 (10.3) | 21 (14.5) | 109 (75.2) | 72 (49.7) | 21 (14.5) | 52 (35.9) | 4 (2.8) | 0 (0) | 141 (97.2) | 28 (19.3) | 40 (27.6) | 77 (53.1) | 106 (73.1) | 0 (0) | 39 (26.9) | 0 (0) | 5 (3.4) | 140 (96.6) | |||
* significantly higher or lower percentage of resistant strains at α = 0.05. AUG: amoxicillin/clavulanic acid (20/10 μg); AP: ampicillin (10 μg); PG: penicillin (10 μg); ENF: enrofloxacin (5 μg); DXT: doxycycline (30 μg): TEC: tetracycline (30 μg); NI: nitrofurantoin (300 μg); C: chloramphenicol (30 μg); E: erythromycin (15 μg); GM: high level gentamicin (120 μg); VA: vancomycin (30 μg); T: teicoplanin (30 μg); LZD: linezolid (30 μg)
Patterns of resistance to antibiotics observed in commensal enterococci (n = 145) isolated from racing pigeons
| Number of antibiotics | Antibiotic combinations (number of resistant isolates) | Total % (n) of resistant isolates |
|---|---|---|
| 9 | Penicillin/Enrofloxacin/Doxycycline/Nitrofurantoin/Chloramphenicol/Tetracycline/Erythromycin/Teicoplanin/Vancomycin (1) | 0.7% (1) |
| 8 | Enrofloxacin/Doxycycline/Nitrofurantoin/Tetracycline/Erythromycin/Teicoplanin/High level gentamicin/Vancomycin (1) | 2.1% (3) |
| Enrofloxacin/Doxycycline/Nitrofurantoin/Chloramphenicol/Tetracycline/Erythromycin/Teicoplanin/Vancomycin (1) | ||
| Penicillin/Enrofloxacin/Doxycycline/Nitrofurantoin/Tetracycline/Erythromycin/Teicoplanin/Vancomycin (1) | ||
| 7 | Enrofloxacin/Doxycycline/Nitrofurantoin/Tetracycline/Erythromycin/Teicoplanin/Vancomycin (3) | 4.1% (6) |
| Enrofloxacin/Doxycycline/Nitrofurantoin/Tetracycline/Teicoplanin/High level gentamicin/Vancomycin (1) | ||
| Enrofloxacin/Doxycycline/Tetracycline/Erythromycin/Teicoplanin/High level gentamicin/Vancomycin (1) | ||
| Penicillin/Enrofloxacin/Doxycycline/Tetracycline/Erythromycin/Teicoplanin/Vancomycin (1) | ||
| 6 | Enrofloxacin/Doxycycline/Nitrofurantoin/Tetracycline/Teicoplanin/Vancomycin (2) | 5.5% (8) |
| Enrofloxacin/Doxycycline/Nitrofurantoin/ChloramphenicoL/Erythromycin/Teicoplanin (1) | ||
| Penicillin/Enrofloxacin/Doxycycline/Nitrofurantoin/Erythromycin/Teicoplanin (1) | ||
| Enrofloxacin/Doxycycline/Nitrofurantoin/Erythromycin/Teicoplanin/Vancomycin (1) | ||
| Enrofloxacin/Doxycycline/Tetracycline/Erythromycin/Teicoplanin/Vancomycin (1) | ||
| Enrofloxacin/Doxycycline/Chloramphenicol/Tetracycline/Teicoplanin/Vancomycin (1) | ||
| Doxycycline/Nitrofurantoin/Tetracycline/Teicoplanin/High level gentamicin/Vancomycin (1) | ||
| 5 | Enrofloxacin/Doxycycline/Chloramphenicol/Erythromycin/Teicoplanin (8) | 17.2% (25) |
| Enrofloxacin/Doxycycline/Nitrofurantoin/Erythromycin/Teicoplanin (5) | ||
| Enrofloxacin/Doxycycline/Tetracycline/Teicoplanin/Vancomycin (4) | ||
| Enrofloxacin/Doxycycline/Tetracycline/Erythromycin/Teicoplanin (3) | ||
| Enrofloxacin/Doxycycline/Erythromycin/Teicoplanin/Vancomycin (3) | ||
| Enrofloxacin/Doxycycline/Nitrofurantoin/Tetracycline/Teicoplanin (1) | ||
| Enrofloxacin/Doxycycline/Chloramphenicol/Tetracycline/Teicoplanin (1) | ||
| 4 | Enrofloxacin/Doxycycline/Erythromycin/Teicoplanin (31) | 29% (42) |
| Enrofloxacin/Doxycycline/Nitrofurantoin/Teicoplanin (6) | ||
| Enrofloxacin/Doxycycline/Teicoplanin/Vancomycin (2) | ||
| Enrofloxacin/Doxycycline/Chloramphenicol/Teicoplanin (1) | ||
| Enrofloxacin/Nitrofurantoin/Tetracycline/Vancomycin (1) | ||
| Doxycycline/Tetracycline/Teicoplanin/Vancomycin (1) | ||
| 3 | Enrofloxacin/Doxycycline/Teicoplanin (11) | 16.6% (24) |
| Doxycycline/Erythromycin/Teicoplanin (6) | ||
| Enrofloxacin/Nitrofurantoin/Erythromycin (3) | ||
| Enrofloxacin/Nitrofurantoin/Tetracycline (1) | ||
| Doxycycline/Chloramphenicol/Teicoplanin (1) | ||
| Doxycycline/Teicoplanin/Vancomycin (1) | ||
| Penicillin/Doxycycline/Teicoplanin (1) | ||
| 2 | Enrofloxacin/Nitrofurantoin (6) | 5.5% (8) |
| Doxycycline/Teicoplanin (2) | ||
| 1 | Enrofloxacin (12) | 12.4% (18) |
| Nitrofurantoin (6) | ||
| 0 | 0 | 6.9% (10) |
The prevalence of Enterococcus-associated vancomycin resistance genes in healthy racing pigeons
| No. of isolates | Number (%) of isolates harbouring the | ||||
|---|---|---|---|---|---|
| 50 | 0 | 5 (10%) | 8 (16%) | 1 (2%) | |
| 30 | 0 | 0 | 4 (13.3%) | 6 (20%)*↑ | |
| 17 | 0 | 0 | 2 (11.8%) | 0 (0%) | |
| 17 | 0 | 0 | 2 (11.8%) | 0 (0%) | |
| 13 | 0 | 0 | 9 (69.2%)*↑ | 0 (0%) | |
| 7 | 0 | 0 | 0 (0%) | 0 (0%) | |
| 5 | 0 | 0 | 0 (0%) | 5 (100%)*↑ | |
| 3 | 0 | 0 | 2 (66.7%) | 0 (0%) | |
| 3 | 0 | 0 | 0 (0%) | 0 (0%) | |
| Total | 145 | 0 | 5 (3.4%) | 27 (18.6%) | 12 (8.3%) |
* significantly higher percentage of isolates with van gene at α = 0.05